thiazoles has been researched along with Hodgkin Disease in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Gopas, J; Gopinath, P; Muraleedharan, KM; Nandakumar, N | 1 |
Engert, A; Gasser, S; Hansen, HP; Reiners, KS; Sauer, M; von Strandmann, EP | 1 |
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
4 other study(ies) available for thiazoles and Hodgkin Disease
Article | Year |
---|---|
Benzisothiazolone Derivatives Exhibit Cytotoxicity in Hodgkin's Lymphoma Cells through NF-κB Inhibition and are Synergistic with Doxorubicin and Etoposide.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Doxorubicin; Drug Synergism; Etoposide; Hodgkin Disease; Humans; NF-kappa B; Thiazoles | 2020 |
Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro.
Topics: Blotting, Western; Cell Line, Tumor; DNA Damage; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Immunity, Innate; Inhibitor of Apoptosis Proteins; NK Cell Lectin-Like Receptor Subfamily K; Thiazoles; Tumor Necrosis Factor-alpha; Up-Regulation | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |